Koshizaka, M., Ishikawa, K., Ishibashi, R., Maezawa, Y., Sakamoto, K., Uchida, D., Nakamura, S., Yamaga, M., Yokoh, H., Kobayashi, A., Onishi, S., Kobayashi, K., Ogino, J., Hashimoto, N., Tokuyama, H., Shimada, F., Ohara, E., Ishikawa, T., Shoji, M., Ide, S., Ide, K., Baba, Y., Hattori, A., Kitamoto, T., Horikoshi, T., Shimofusa, R., Takahashi, S., Nagashima, K., Sato, Y., Takemoto, M., Newby, L. K., Yokote, K., & , (2019). comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study). Diabetes, obesity & metabolism, 21(8), 1990–1995. http://access.bl.uk/ark:/81055/vdc_100086845494.0x000023